Crossmark

Clinical utility of the S3-score for molecular prediction of outcome in non-metastatic and metastatic clear cell renal cell carcinoma

Crossref DOI link: https://doi.org/10.1186/s12916-018-1088-5

Published Online: 2018-07-05

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Büttner, Florian

Winter, Stefan

Rausch, Steffen

Hennenlotter, Jörg

Kruck, Stephan

Stenzl, Arnulf

Scharpf, Marcus

Fend, Falko

Agaimy, Abbas

Hartmann, Arndt

Bedke, Jens

Schwab, Matthias

Schaeffeler, Elke
Funding

Funding for this research was provided by:

Robert Bosch Stiftung

Deutsche Forschungsgemeinschaft (DFG SFB685 C05)

Deutsche Gesellschaft für Urologie (RaS1/FE-14)

ICEPHA Graduate School Tuebingen-Stuttgart
License Information

Text and Data Mining valid from 2018-07-05
More Information

Article History

Received: 14 August 2017

Accepted: 1 June 2018

First Online: 5 July 2018

Ethics approval and consent to participate

: Use of the primary tumor samples with ccRCC histology and metastases samples of patients treated at the Department of Urology, University Hospital Tuebingen, Germany, was approved by the ethics committee of the University of Tuebingen (no. 379/2010/BO2) and informed written consent was provided by each subject prior to surgical resection.

: Not applicable

: JB: consultancies, honoraria or study participation from Bayer, BMS, GSK, Immatics, Novartis, Pfizer, and Roche. AS: consultancies, honoraria or study participation from Bayer, BMS, Immatics, Novartis, Pfizer, and Roche. All other authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.